Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy

详细信息    查看全文

• 作者：Lee Cheng Phua (1)
  Mainak Mal (1)
  Poh Koon Koh (2)
  Peh Yean Cheah (2)
  Eric Chun Yong Chan (1)
  Han Kiat Ho (1)
  
• 关键词：Equilibrative nucleoside transporter ; 5 ; fluorouracil ; Colorectal cancer ; Metabonomics ; Metabolomics
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2013
• 出版时间：March 2013
• 年：2013
• 卷：71
• 期：3
• 页码：817-823
• 全文大小：262KB
• 参考文献：1. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A (1999) Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17:1760-770
  2. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD (2004) The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447:735-43 CrossRef
  3. Boleti H, Coe IR, Baldwin SA, Young JD, Cass CE (1997) Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology 36:1167-179 CrossRef
  4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-047 CrossRef
  5. Muggia FM (1991) New drugs, concepts and results in cancer chemotherapy. Springer, Netherlands CrossRef
  6. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-47
  7. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-412
  8. Kong W, Engel K, Wang J (2004) Mammalian nucleoside transporters. Curr Drug Metab 5:63-4 CrossRef
  9. Mal M, Koh PK, Cheah PY, Chan EC (2012) Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Anal Bioanal Chem 403:483-93 CrossRef
  10. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L, Danenberg PV (1998) High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4:2371-376
  11. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ (2000) Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 60:6075-079
  12. Tsuji T, Sawai T, Takeshita H, Nakagoe T, Hidaka S, Yamaguchi H, Yasutake T, Nagayasu T, Tagawa Y (2004) Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. Cancer Chemother Pharmacol 54:531-36 CrossRef
  13. Tsujie M, Nakamori S, Nakahira S, Takahashi Y, Hayashi N, Okami J, Nagano H, Dono K, Umeshita K, Sakon M, Monden M (2007) Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res 27:2241-249
  14. Woodahl EL, Wang J, Heimfeld S, Ren AG, McCune JS (2008) Imatinib inhibition of fludarabine uptake in T-lymphocytes. Cancer Chemother Pharmacol 62:735-39 y">CrossRef
  15. Xin H, Jiang X, Gu J, Sha X, Chen L, Law K, Chen Y, Wang X, Jiang Y, Fang X (2011) Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32:4293-305 CrossRef
  16. Yao SY, Ng AM, Cass CE, Baldwin SA, Young JD (2011) Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J biol chem 286:32552-2562 CrossRef
  17. Yoshinare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H, Kitajima M, Takechi T, Fukushima M (2003) Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci 94:633-38 CrossRef
  
• 作者单位：Lee Cheng Phua (1)
  Mainak Mal (1)
  Poh Koon Koh (2)
  Peh Yean Cheah (2)
  Eric Chun Yong Chan (1)
  Han Kiat Ho (1)
  
  1. Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Singapore
  2. Department of Colorectal Surgery, Colorectal Cancer Research Laboratory, Singapore General Hospital, Outram Road, Block 6 Level 7, Singapore, 169608, Singapore
  
• ISSN：1432-0843

文摘

Resistance to 5-fluorouracil (5FU) poses a constant challenge to the management of colorectal cancer (CRC). Consistent efforts were called for to identify molecular markers that can effectively predict patients-response. This study investigated the role of nucleoside transporters, particularly human equilibrative nucleoside transporter 1 (hENT1), in predicting clinical treatment outcome with 5FU-based therapy. Expression of a panel of nucleoside transporters in biopsied tumors from 7 CRC patients was measured by real-time PCR prior to 5FU-based chemotherapy. To provide mechanistic support for the role of hENT1 in 5FU resistance, cell viability of Caco-2 cells was measured, following incubation with varying concentrations of 5FU and a hENT1 inhibitor. Biopsied tumors were further subjected to global metabonomic profiling using gas chromatography/mass spectrometry. High hENT1 levels in tumor tissue correlated with poor clinical response to 5FU. Corroborating with the clinical findings, chemical inhibition of hENT1 in Caco-2 cells resulted in an augmentation of 5FU efficacy. Metabonomic profiling revealed that the pretreatment metabotype associated with non-responders to 5FU therapy was distinct from metabotype of responders (partial least-squares discriminant analysis Q 2 (cumulative)?=?0.898, R 2 X?=?0.513, R 2 Y?=?0.996). This is the first clinical report on the relationships of intratumoral expression of nucleoside transporters and tumor metabotype with response to 5FU among CRC patients. Coupled to the in vitro findings, our preliminary data suggested hENT1 to be a potential codeterminant of clinical response to 5FU.